Crescent Biopharma (C68) Price & Analysis

2 Followers

C68 Stock Chart & Stats

€13.70

€1.10(8.46%)

At close: Jul 24 4:00 PM EDT

€13.70

€1.10(8.46%)

Day’s Range― - ―

52-Week Range€6.70 - €22.80

Previous CloseN/A

Volume0.00

Average Volume (3M)22.00

Market Cap

€574.53M

Enterprise Value€383.42

Total Cash (Recent Filing)€171.59M

Total Debt (Recent Filing)€1.44M

Price to Earnings (P/E)―

Beta0.68

Next Earnings

Nov 05, 2026

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.72

Shares Outstanding37,143,940

10 Day Avg. Volume21

30 Day Avg. Volume22

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.61

Price to Sales (P/S)11.39

P/FCF Ratio-0.86

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€25.31

Price Target Upside84.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-2.32

Revenue Forecast (FY)€1.60M

Bulls Say, Bears Say

Bulls Say

Low LeverageThe very low debt burden limits interest and refinancing pressure, giving Crescent Biopharma greater financial flexibility while it funds development. However, this strength is partly offset by ongoing losses and declining equity.

Modest Revenue GrowthRevenue increased year over year, indicating some progress in commercial or partnership-related activity. Sustained growth could improve operating leverage over time, although the current revenue base remains too small to absorb the company’s expense structure.

Governance ContinuityShareholder approval of the board, auditor, and compensation program provides continuity in oversight and reporting. Annual advisory votes on pay also create a recurring accountability mechanism that can support alignment between management and investors.

Bears Say

Severe Operating LossesLosses are extraordinarily large relative to revenue, showing that operating expenses substantially exceed the company’s current scale. Without a major improvement in product economics, revenue growth, or cost control, profitability remains a distant and uncertain objective.

Heavy Cash BurnPersistent negative operating and free cash flow indicates that the business cannot currently fund itself from operations. The deterioration in free cash flow increases dependence on financing, partnerships, or spending reductions and raises the risk of dilution or constrained development.

Eroding Equity BaseDeclining equity is consistent with sustained losses and potentially financing-related effects, reducing the capital cushion available to support operations. Continued erosion could weaken financial resilience and increase the company’s need to raise capital on unfavorable terms.

Crescent Biopharma News

Crescent Biopharma reports Q2 EPS (74c), consensus (64c)

“We have continued to demonstrate exceptional execution and are on track for multiple key clinical data readouts across...

29d ago

CBIO

Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Crescent Biopharma today and set a price target...

29d ago

CBIO

Crescent Biopharma, Inc. (CBIO) Q2 Earnings Cheat Sheet

Crescent Biopharma, Inc. (CBIO) is scheduled to report 2nd quarter earnings on 07/30/2026. Regarding Q2 estimates, Wall Street...

1M ago

CBIO

Travelers, TransDigm, Cytokinetics, Global-e, Crescent Shock Moves

Insiders have been trading these 5 stocks: (($TRV)), (($TDG)), (($CYTK)), (($GLBE)) and (($CBIO)). Here is a breakdown of...

1M ago

TDG

TRV

Fourteen new option listings and one option delisting on July 22nd

New option listings for July 22nd include Tradr 2X Short AAOI Daily ETF (AAOZ), Alpha Cognition Inc (ACOG),...

1M ago

ACOG

ARTV

Crescent Biopharma 8.095M share Spot Secondary priced at $14.50

Jefferies, TD Cowen, Guggenheim and Cantor Fitzgerald acted as joint book running managers for the offering. Published first...

1M ago

CBIO

Crescent Biopharma files ordinary shares offering, no amount given

Jefferies, TD Cowen, Guggenheim, and Cantor are acting as joint book-running managers. LifeSci Capital is acting as a...

1M ago

CBIO

BTIG says others may be interested in Apogee Therapeutics

BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis...

2M ago

JNJ

NVS

Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CPB) ), ( ($CBIO) ), ( ($CRDF) ), ( ($SHW)...

3M ago

CPB

SHW

Crescent Biopharma shareholders back directors, pay and auditor

Crescent Biopharma ( ($CBIO) ) just unveiled an update. On June 2, 2026, Crescent Biopharma, Inc. held its...

3M ago

CBIO

Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Crescent Biopharma (CBIO) to Neutral from Buy without a price target saying the ivonescimab copycat...

3M ago

CBIO

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

Reports Q1 revenue $1.04M, consensus $357,140. “Crescent’s execution on the advancement of our pipeline this quarter positions us...

4M ago

CBIO

Crescent Biopharma management to meet with Cantor Fitzgerald

Meeting to be held in San Francisco on April 14, in Denver on April 15 and in New...

5M ago

CBIO

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Crescent Biopharma (CBIO) to $22 from $25 and keeps a...

6M ago

CBIO

C68 FAQ

What was Crescent Biopharma’s price range in the past 12 months?

Crescent Biopharma lowest stock price was €6.70 and its highest was €22.80 in the past 12 months.

What is Crescent Biopharma’s market cap?

Crescent Biopharma’s market cap is €574.53M.

When is Crescent Biopharma’s upcoming earnings report date?

Crescent Biopharma’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.

How were Crescent Biopharma’s earnings last quarter?

Crescent Biopharma released its earnings results on Jul 30, 2026. The company reported -€0.634 earnings per share for the quarter, missing the consensus estimate of -€0.631 by -€0.003.

Is Crescent Biopharma overvalued?

According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Crescent Biopharma pay dividends?

Crescent Biopharma does not currently pay dividends.

What is Crescent Biopharma’s EPS estimate?

Crescent Biopharma’s EPS estimate is -0.58.

How many shares outstanding does Crescent Biopharma have?

Crescent Biopharma has 37,143,940 shares outstanding.

What happened to Crescent Biopharma’s price movement after its last earnings report?

Crescent Biopharma reported an EPS of -€0.634 in its last earnings report, missing expectations of -€0.631. Following the earnings report the stock price went down -11.765%.

Which hedge fund is a major shareholder of Crescent Biopharma?

Currently, no hedge funds are holding shares in DE:C68

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Crescent Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

16.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Crescent Biopharma

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Crescent Biopharma (C68) Earnings & Revenues

Historic Earnings Reports

C68 Stock 12 Month Forecast

Average Price Target

€25.31

▲(84.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","13":"€13","19":"€19","25":"€25","31":"€31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.0233325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.30538025,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€25.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.1608565,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13,19,25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.478717884615385,14.857435769230769,16.236153653846152,17.61487153846154,18.993589423076923,20.37230730769231,21.751025192307694,23.129743076923077,24.50846096153846,25.887178846153844,27.26589673076923,28.64461461538462,{"y":30.0233325,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.11579848076923,14.131596961538461,15.14739544230769,16.16319392307692,17.178992403846152,18.194790884615383,19.210589365384614,20.226387846153845,21.242186326923076,22.257984807692306,23.273783288461537,24.289581769230765,{"y":25.30538025,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,12.950835115384615,13.801670230769231,14.652505346153847,15.503340461538462,16.354175576923076,17.20501069230769,18.055845807692307,18.906680923076923,19.75751603846154,20.608351153846154,21.45918626923077,22.310021384615386,{"y":23.1608565,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.174,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >